First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Published:2017-12-15 Issue:2 Volume:8 Page:184-195
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Sullivan Ryan J.,Infante Jeffrey R.,Janku Filip,Wong Deborah Jean Lee,Sosman Jeffrey A.,Keedy Vicki,Patel Manish R.,Shapiro Geoffrey I.,Mier James W.,Tolcher Anthony W.,Wang-Gillam Andrea,Sznol Mario,Flaherty Keith,Buchbinder Elizabeth,Carvajal Richard D.,Varghese Anna M.,Lacouture Mario E.,Ribas Antoni,Patel Sapna P.,DeCrescenzo Gary A.,Emery Caroline M.,Groover Anna L.,Saha Saurabh,Varterasian Mary,Welsch Dean J.,Hyman David M.,Li Bob T.

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 311 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapy Innovations for Melanoma;Hematology/Oncology Clinics of North America;2024-10

2. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09

3. Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature;Drugs in R&D;2024-08-23

4. Advances in Personalized Oncology;Cancers;2024-08-16

5. Scalable and universal prediction of cellular phenotypes;2024-08-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP